Monteris Medical is a neurosurgical company with a focus on creating unique and innovative technology to treat serious brain disorders. Their flagship product, the Neuroblate Thermal Therapy System creates minimally invasive treatments for soft tissue and brain lesions
Diagnovus is a specialized molecular diagnostic company, focused on delivering personalized diagnostic information and services to physicians treating patients suffering from rare, orphan and less frequent diseases. We are privileged for the opportunity to serve patients and the physicians treating them.
Regenesis Biomedical’s Provant Therapy System is FDA approved for the palliative treatment of post-operative pain and edema in superficial soft tissue. Post surgery, many tissues may be moved around or inflamed, but Provant helps reduce the pain by inducing endogenous opioids. This prescription only device exposes tissue to electromagnetic energy using an optimized energy pulse.
Preliminary data in preclinical models of severe complex wounds suggests that human VSELs™ (very small embryonic like stem cells) accelerates wound healing. NeoStem hopes to advance into early clinical studies to assess therapeutic potential of VSEL technology.
Early results for the new flu drug FluCide® found to be safe in a non-GLP small animal safety/ toxicology study. These preliminary results support the company’s earlier reports of the FluCide® drug being effective in animal models of different influenza A virus strains. NanoViricides is also developing drugs against HIV/AIDS (HivCide™-I), Dengue (DengueCide™-I), and External Eye Viral disease (EKC-Cide™-I), amongst other viral diseases.
STR has started a clinical trial in Europe for its ACL device and has successfully implanted the device in 7 patients as of October 2013. Their device utilizes a synthetic scaffold that regenerates the entire ligament tissue resulting in better chances of full recovery.
Profound’s unique device for Prostate cancer treatment is currently in Phase I clinical trials in Europe and Canada. Profound has also received FDA approval to conduct clinical trials in U.S that will begin soon in 2013. The company is on fast track to begin commercialization in Europe by 2015.
NEW YORK, Oct. 15, 2013 – OneMedForum announced today that a major theme of its 7th annual healthcare investing conference will be to provide investors with an outlook about how the healthcare system will function post-Obamacare. Moreover, it will also address the new financing opportunities created by the JOBS Act and feature innovatively growing companies that are best positioned to succeed in this new environment.
Orexigen Therapeutics is a biopharmaceutical company that focuses its attention on the treatment of one of the most common diseases in existence today, obesity.
OneMedPlace announces program for the Seventh Annual OneMedForum: Investing in Healthcare 2014, Jan. 13-15
Copyright © 2024 | WordPress Theme by MH Themes